Posted by SLS on October 7, 2021, at 18:06:48
In reply to Re: Real World data and new drugs, posted by undopaminergic on October 7, 2021, at 10:31:17
> > I post regularly regarding the higher rate of reported placebo effect and lower rate of efficacy as reported in today's antidepressant clinical trials compared to those conducted in the 1970s and 1980s. To explain this, one must take into consideration the differences in subject selection and inclusion criteria. Today's trials dilute the subject population by including subjects who do not really have Major Depresive Disorder. They are experimenting using people who don't really have the illness that they are supposed to be studying.
> >
> > Oh, well.
> >
> > Money.
> >
> > Investigators are paid by the numbers of participants they recruit.
> >
> >
> > - Scott
>
> Money? Isn't there more money to be made from showing efficacy of the drug? So, they would want to choose subjects that will respond better to the drug, wouldn't they?
>
> -undopaminergic
UD,The clinical trial company gets paid by the number of subjects they recruit. They really don't give a damn whether the drug works or not, as long as they get paid and their contract renewed.
-----
Prospective participant: "I'm depressed."
Screening coordinator: "Okay. That's good enough. You are definitely eligible for our study. Just sign this paper."
-----
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.The only thing necessary for the triumph of evil is that good men do nothing.
poster:SLS
thread:1117173
URL: http://www.dr-bob.org/babble/20210723/msgs/1117188.html